Abstract 316TiP
Background
Phase 2 studies (NCT02296684 and NCT02641093) with neoadjuvant and adjuvant pembro have demonstrated pathological response (PR) and acceptable safety in pts with high-risk resectable LA HNSCC. The randomized, global, open-label, phase 3 KEYNOTE-689 trial (NCT03765918) will evaluate the efficacy and safety of neoadjuvant pembro and adjuvant pembro plus SOC in pts with previously untreated resectable LA HNSCC.
Trial design
Pts will be randomly assigned 1:1 to two arms. In arm A, pts will receive neoadjuvant pembro (200 mg Q3W, 2 cycles), followed by surgical resection, then SOC plus adjuvant pembro (200 mg Q3W, 15 cycles). In arm B, pts will undergo surgical resection followed by adjuvant SOC without pembro. SOC is radiotherapy (RT) alone (pts at low risk) or RT plus concurrent cisplatin (3 cycles of 100 mg/m2 Q3W) (pts at high risk). RT is standard fractionation at 2 Gy/fraction for 30, 33, or 35 fractions (60 Gy, 66 Gy, or 70 Gy) for pts at low risk or high risk or with gross residual disease, respectively. Randomization will be stratified by primary tumor site (oropharynx/oral cavity vs larynx vs hypopharynx), tumor stage (III vs IVA), and HPV p16 status (oropharynx p16–positive vs oropharynx p16–negative or larynx/hypopharynx/oral cavity). Eligible pts are adults with newly diagnosed, resectable, nonmetastatic stage III/IVA HNSCC (AJCC Cancer Staging Manual, 8th edition), evaluable tumor burden, and ECOG PS 0 or 1 who are eligible for primary surgery. Treatment will continue until disease progression, unacceptable toxicity, or decision to withdraw in both arms. Co-primary end points are major PR (≤10% invasive SCC within resected primary tumor and sampled regional lymph nodes per blinded central pathology) and event-free survival. Secondary end points include overall survival, pathological complete response, quality of life, and safety. The first radiologic imaging in arm A will occur after 2 cycles of pembro and before surgery. Postoperative imaging will occur in both arms 12 weeks after SOC, then every 3 months until year 3 and every 6 months thereafter. Recruitment is ongoing; estimated enrollment is ∼700 pts.
Clinical trial identification
NCT03765918.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
E. Cohen: Advisory / Consultancy: Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Incyte; MSD; Merck. R. Uppaluri: Advisory / Consultancy, Research grant / Funding (self): Merck. N. Lee: Advisory / Consultancy: Merck, Merck Serono, Pfizer, Sanofi; Spouse / Financial dependant, Spouse Stockholder: AstraZeneca. W. Westra: Advisory / Consultancy, Travel / Accommodation / Expenses: Merck. R. Haddad: Advisory / Consultancy: Celgene, Merck, Eisai, Bristol-Myers Squibb, AstraZeneca, Pfizer, Loxo, Genentech, Immunomic Therapeutics; Research grant / Funding (institution): Boehringer Ingelheim, Merck, Bristol-Myers Squibb, Celgene, AstraZeneca, VentiRx, Genentech, Pfizer, Kura. C. Le Tourneau: Honoraria (self), Advisory / Consultancy: Merck Serono, Bristol-Myers Squibb, MSD, Amgen, Novartis, Nanobiotix; Travel / Accommodation / Expenses: Bristol-Myers Squibb, Amgen, MSD, Merck Serono. R. Chernock: Advisory / Consultancy: Merck, Roche. Y. Tao: Research grant / Funding (institution): Debiopharma, MSD, Pfizer; Travel / Accommodation / Expenses: MSD, Merck Serono. I. Brana: Advisory / Consultancy: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Bristol-Myers Squibb, AstraZeneca, Merck Serono; Research grant / Funding (self): AstraZeneca, Bristol-Myers Squibb, Celgene, Gliknik, GlaxoSmithKline, Janssen Oncology, Kura, Merck Sharp & Dohme, Novartis, Orion Pharma GmbH, Pfizer; Travel / Accommodation / Expenses: AstraZeneca Spain, Merck Serono. J.Y. Ge: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck Sharp & Dohme. R. Swaby: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. B. Bidadi: Full / Part-time employment: Merck. D. Adkins: Advisory / Consultancy: Pfizer, Eli Lilly, Merck, Celgene; Travel / Accommodation / Expenses: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract